.Pharmacolibrary.Drugs.V_Various.V08C_MagneticResonanceImagingContrastMedia.V08CA03_Gadodiamide.Gadodiamide

Information

name:Gadodiamide
ATC code:V08CA03
route:intravenous
n-compartments2

Gadodiamide is a non-ionic, linear gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to enhance the visibility of internal structures. It is indicated primarily for cranial, spinal, and whole-body MRI for the detection of lesions with abnormal vascularity. Its use has declined in some regions due to concerns of nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment, but it may still be used in clinical practice.

Pharmacokinetics

Pharmacokinetic model and parameters based on healthy adult individuals (nā‰ˆ13-110), both sexes, after intravenous administration of 0.1 mmol/kg.

References

  1. Shellock, FG, & Kanal, E (1999). Safety of magnetic resonance imaging contrast agents. Journal of magnetic resonance imaging : JMRI 10(3) 477–484. DOI:10.1002/(sici)1522-2586(199909)10:3<477::aid-jmri33>3.0.co;2-e PUBMED:https://pubmed.ncbi.nlm.nih.gov/10508312

Revisions


Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos